Encouraging improvements in Treating Lung Cancer

Lung cancer is the biggest killer
in Hong Kong. More than 80 percent of
cases are caused by what is known as
non-small cell carcinoma (NSCLC). But
encouraging advances have been made in
recent years in the treatment of NSCLC.

The current standard way of dealing
with early-stage NSCLC is to resects completely
the part of the organ affected by it. However,
the 5 year survival rate is still less than
satisfactory.

In the past decade, cisplatin-based
chemotherapy had been used on patients
following resection. Their survival rate
is more favorable, and the side effects
from this king of chemotherapy were more
tolerable.

Adjuvant chemotherapy, or additional
chemotherapy, can be considered as part of
standard treatment for younger patients in
early disease stage who have responded well
to resection.

The standard first-line treatment for recurring
or advanced lung cancer is a treatment that uses
a combination of chemotherapy and radiotherapy
for patients in relatively better conditions,
using a combination of platinum and a newer
chemotherapy agent (e.g paclitaxel, docetaxel
or gemcitabine) can further improve their
survival rate.

The treatment of the future for lung cancer
will probably involve the development of novel
molecularly targeted therapies and their
application together with chemotherapy.

Using Bevacizumab, a drug which targets
the angiogenesis in tumors, in conjunction
with chemotherapy have shown very good results,
but this treatment also increases the risk of
haemoptysis, the coughing of blood, which is
life-threatening.

Encouraging improvements have been made
in treating lung cancer in recent years. providing
more options for patients to deal with the
deadly disease, This augurs well for lung
cancer victims who may see some notable
breakthroughs in the near future.

Extract form the health feature by
University of Hong Kong